In this video, senior health-care analyst David Williamson discusses MAP Pharmaceuticals' recent resubmission of Levadex. Watch and find out what tripped up Levadex before, how likely approval is, and what it all means for investors.
Many investors are attracted to MAP and biotechs like it, since they hold the allure of substantial short term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
The article MAPping Out an FDA Approval originally appeared on Fool.com.
Brenton Flynn, Dave Williamson, and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend MannKind. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.